News / Press Release

Flagship Biosciences finds Arizona a great home for serving pathology digitally

June 5, 2012

While most of Flagship’s customers are at biotech and pharma locations around the world, there has been some strong collaborations formed with Arizona biotech firms. “The collaboration spirit in Arizonais remarkable” said Steve Potts. “the amount of additional business that Arizona groups like TGEN generate for other local biotech providers is astonishing. It has been an honor to work with Steve Gately’s TGEN Drug Development group (TD2), with a number of completed projects where TD2 applies their unique oncology expertise and Flagship adds our quantitative pathology.”

Arizona has a number of worldclass specialty contract research organizations, including TD2 in Oncology, Flagship Biosciences in pathology, Imaging Endpoints in radiology, Medelis in oncology and dermatology clinical trials, and SDC in statistics. The need for best-in-class specialty service is growing in the pharmaceutical industry, and Arizona with a skilled workforce, strong collaborative spirit, and industry friendly environment is positioned to lead in this area.

About Translational Drug Development (TD2)

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

About TD2

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

Contact
Tara Franks
602-358-8322
Get free tips, tools and resources by subscribing to the TD2 Newsletter: